血清TFF1、CCL22及TGF-β1水平与口腔癌患者临床特征、预后及新辅助化疗疗效的关系

doi:10.19438/j.cjoms.2026.05.010

摘要/Abstract

摘要： 目的：探讨血清三叶因子1（TFF1）、CC趋化因子配体22（CCL22）、转化生长因子β1（TGF-β1）水平与口腔癌患者临床特征、预后及新辅助化疗疗效的相关性。方法：选取2022年1月—2023年12月河南科技大学第一附属医院收治的口腔癌患者192例,根据随访结局分为预后不良组（76例）和预后良好组（116例）。其中65例接受新辅助化疗,根据疗效分为完全缓解组（34例）和未完全缓解组（31例）。比较不同临床特征、预后、新辅助化疗疗效患者的血清TFF1、CCL22、TGF-β1水平。采用二元logistic回归分析TFF1、CCL22、TGF-β1水平与患者预后的关系,并绘制受试者工作特征（ROC）曲线,以曲线下面积（AUC）评估各指标单独及联合检测对患者预后不良的预测价值。结果：中低分化、临床分期Ⅲ~Ⅳ期、有颈淋巴结转移的口腔癌患者血清TFF1、CCL22、TGF-β1水平均显著高于高分化、Ⅰ~Ⅱ期、无颈淋巴结转移的患者（P<0.01）。预后不良组患者血清TFF1、CCL22、TGF-β1水平均显著高于预后良好组（P<0.01）。二元logistic回归分析结果显示,TFF1、CCL22、TGF-β1均为口腔癌患者预后不良的独立影响因素（P<0.05）。ROC曲线显示,TFF1、CCL22、TGF-β1联合检测预测口腔癌患者预后的AUC为0.921（95%CI：0.879-0.964）,高于三者单独检测。未完全缓解组患者血清TFF1、CCL22、TGF-β1水平均显著高于完全缓解组（P<0.01）。结论：血清TFF1、CCL22、TGF-β1水平与口腔癌患者的分化程度、临床分期及颈淋巴结转移密切相关,是影响患者预后及新辅助化疗疗效的重要因素。联合检测具有较高的预后预测价值。

关键词: 三叶因子1, CC趋化因子配体22, 转化生长因子β1, 口腔癌, 新辅助化疗

Abstract: PURPOSE: To investigate the relationship between serum trefoil factor 1 (TFF1), CC chemokine ligand 22 (CCL22), and transforming growth factor-β1 (TGF-β1) levels and the clinical characteristics, prognosis, and efficacy of neoadjuvant chemotherapy in patients with oral cancer. METHODS: A total of 192 oral cancer patients admitted to the First Affiliated Hospital of Henan University of Science and Technology from January 2022 to December 2023 were enrolled and classified into a poor-prognosis group (n=76) and a good-prognosis group (n=116) based on follow-up outcomes. Among them, 65 patients received neoadjuvant chemotherapy and were further divided into a complete response group (n=34) and an incomplete response group (n=31). Serum levels of TFF1, CCL22, and TGF-β1 were compared across patients with different clinical characteristics, prognoses, and neoadjuvant chemotherapy responses. Binary logistic regression analysis was performed to examine the relationship between these biomarker levels and patients’ prognosis, and receiver operating characteristic (ROC) curves were plotted to evaluate the predictive value of each marker alone or in combination for poor prognosis, using the area under the curve (AUC). RESULTS: The serum TFF1, CCL22, and TGF-β1 levels in patients with poorly differentiated, clinical stage Ⅲ-Ⅳ, and cervical lymph node metastasis were significantly higher than those in patients with well-differentiated, clinical stage Ⅰ-Ⅱ, and non-cervical lymph node metastasis (P<0.01). The levels of serum TFF1, CCL22, and TGF-β1 in the poor prognosis group of oral cancer patients were significantly higher than those in the good prognosis group, and the differences were statistically significant (P<0.01). Binary logistic regression analysis results showed that TFF1, CCL22 and TGF-β1 were independent influencing factors for poor prognosis in oral cancer patients (P<0.05). ROC curve showed that the AUC of combined detection of TFF1, CCL22 and TGF-β1 for predicting the prognosis of oral cancer patients was 0.921 (95%CI: 0.879-0.964), which was higher than that of the three tests alone. The levels of serum TFF1, CCL22 and TGF-β1 in the incomplete response group of oral cancer patients were significantly higher than those in the complete response group, and the differences were statistically significant (P<0.01). CONCLUSIONS: Serum levels of TFF1, CCL22, and TGF-β1 are closely correlated with the differentiation degree, clinical stage, and cervical lymph node metastasis in patients with oral cancer, and they are important factors affecting patients' prognosis and the efficacy of neoadjuvant chemotherapy. Combined detection of these biomarkers exhibits high prognostic predictive value.

Key words: TFF1, CCL22, TGF-β1, Oral cancer, Neoadjuvant chemotherapy

中图分类号:

R739.8

王岳森, 李宏, 武宝峰. 血清TFF1、CCL22及TGF-β1水平与口腔癌患者临床特征、预后及新辅助化疗疗效的关系[J]. 中国口腔颌面外科杂志, 2026, 24(5): 501-506.

Wang Yuesen, Li Hong, Wu Baofeng. Relationship between serum TFF1, CCL22, and TGF-β1 levels and the clinical characteristics, prognosis, and efficacy of neoadjuvant chemotherapy in patients with oral cancer[J]. China J Oral Maxillofac Surg, 2026, 24(5): 501-506.

参考文献

[1] Rodríguez-Molinero J, Migueláñez-Medrán BDC, Puente-Gutiérrez C, et al.Association between oral cancer and diet: an update[J]. Nutrients, 2021, 13(4): 1299.
[2] Nagao T, Warnakulasuriya S.Screening for oral cancer: future prospects, research and policy development for Asia[J]. Oral Oncol, 2020, 105: 104632.
[3] 张鑫睿, 江旖婷, 张晗之, 等. 28例晚期口腔鳞癌患者新辅助化疗围化疗期营养状况及生活质量评估[J]. 中国口腔颌面外科杂志, 2020, 18(6): 516-520.
Zhang XR, Jiang YT, Zhang HZ, et al.Nutritional status and quality of life in 28 patients with advanced oral squamous cell carcinoma during neoadjuvant chemotherapy[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(6): 516-520.
[4] Luo T, Huang C, Zhou R, et al.Predicting complications in elderly patients undergoing oral cancer resection with free flap reconstruction in China: a retrospective cohort study using the modified Frailty Index and Prognostic Nutritional Index[J]. BMJ Open, 2024, 14(12): e085985.
[5] 赵建敏, 陈浩, 王凌, 等. 血清TFF1、CCL22的表达对口腔癌患者预后的预测价值[J]. 实用癌症杂志, 2024, 39(9): 1564-1566.
Zhao JM, Chen H, Wang L, et al.The prognostic value of serum TFF1 and CCL22 expression in patients with oral cancer[J]. The Practical Journal of Cancer, 2024, 39(9): 1564-1566.
[6] Liu A, Yu C, Qiu C, et al.PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis[J]. Oncogene, 2023, 42(19):1572-1584.
[7] de Streel G, Lucas S. Targeting immunosuppression by TGF-β1 for cancer immunotherapy[J]. Biochem Pharmacol, 2021, 192: 114697.
[8] Zhou W, Zhang X, Feng Y, et al.The CC ligand chemokine family members CCL17/CCL22 predict the survival and response to immune checkpoint blockade therapy of patients with head and neck squamous cell carcinoma[J]. Curr Probl Cancer, 2022, 46(6):100896.
[9] 董怡君, 宋柳, 景星滔, 等. 《2023NCCN头颈癌临床实践指南(第1版)》更新解读[J]. 西部医学, 2023, 35(10): 1412-1417.
Dong YJ, Song L, Jing XT, et al.Interpretation of updated 2023 NCCN clinical practice guidelines for head and neck cancers(1st edition)[J]. Medical Journal of West China, 2023, 35(10): 1412-1417.
[10] Tran Q, Maddineni S, Arnaud EH, et al.Oral cavity cancer in young, non-smoking, and non-drinking patients: a contemporary review[J]. Crit Rev Oncol Hematol, 2023, 190: 104112.
[11] Ong YLR, Tivey D, Huang L, et al.Factors affecting surgical mortality of oral squamous cell carcinoma resection[J]. Int J Oral Maxillofac Surg, 2021, 50(1): 1-6.
[12] 陈彬, 王涛, 王琰, 等. 血清TFF1、Smad4、CCL22、TPS水平与口腔癌患者临床病理特征及预后的关系研究[J]. 空军军医大学学报, 2025, 46(7): 931-936.
Chen B, Wang T, Wang Y, et al.Study on the relationship between serum TFF1, Smad4, CCL22 and TPS levels and clinicopathological features and prognosis of patients with oral cancer[J]. Journal of Air Force Medical University, 2025, 46(7): 931-936.
[13] Shekarriz R, Kochaki N, Eslami-Jouibari M, et al.TFF1 gene single nucleotide polymorphism (rs3761376) and colorectal cancer risk[J]. Mol Biol Rep, 2022, 49(10): 10127-10131.
[14] 王晓龙, 陈亮, 曹洪涛, 等. CC趋化因子配体22在胃癌病人外周血中的表达及意义[J]. 临床外科杂志, 2021, 29(10): 957-959.
Wang XL, Chen L, Cao HT, et al.Expression and efficacy of CCL22 in serum of gastric cancer[J]. Journal of Clinical Surgery, 2021, 29(10): 957-959.
[15] 张乘源, 石雅馨, 张东, 等. 基于TGFβ1介导的上皮-间充质转化探讨重楼皂苷Ⅰ抑制胶质母细胞瘤侵袭、迁移的分子机制[J]. 中药新药与临床药理, 2024, 35(11): 1687-1697.
Zhang CY, Shi YX, Zhang D, et al.Exploring the mechanism of polyphyllin Ⅰ on inhibition of glioblastoma invasion and migration based on TGF-β1-mediated epithelial-mesenchymal transition[J]. Traditional Chinese Drug Research and Clinical Pharmacology, 2024, 35(11): 1687-1697.
[16] 张志锋, 孙业富, 沈预程, 等. 乳腺癌患者血清三叶因子1水平及其与乳腺癌新辅助化疗效果和预后的关系[J]. 广西医学, 2022, 44(5): 501-505, 515.
Zhang ZF, Sun YF, Shen YC, et al.Serum trefoil factor 1 level of patients with breast cancer and its relationship with efficacy and prognosis of neoadjuvant chemotherapy in breast cancer[J]. Guangxi Medical Journal, 2022, 44(5): 501-505, 515.
[17] Wang J, Huang P, Pan X, et al.Resveratrol reverses TGF-β1-mediated invasion and metastasis of breast cancer cells via the SIRT3/AMPK/autophagy signal axis[J]. Phytother Res, 2023, 37(1): 211-230.
[18] Lin G, Wang H, Zhang D, et al.TGF-β1 up-regulates PLAU expression to promote invasion and migration of oral squamous cell carcinoma[J]. J Oral Pathol Med, 2026, 55(3): 297-307.
[19] 史伟红, 刘严, 刘雪, 等. TGF-β1对舌鳞癌细胞生物学行为的影响及机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(5): 437-442.
Shi WH, Liu Y, Liu X, et al.Activation of ERK1/2 pathway by TGF-β1 regulation of CD155 expression in squamous cell carcinoma of the tongue[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(5): 437-442.
[20] Chen Y, Du H, Wei B, et al.Development and validation of risk-stratification delirium prediction model for critically ill patients: a prospective, observational, single-center study[J]. Medicine (Baltimore), 2017, 96(29): e7543.
[21] 刘芳芳, 李敏学, 闫毅超. 持续动脉灌注新辅助化疗治疗中晚期口腔癌的疗效观察[J]. 中国肿瘤临床与康复, 2022, 29(1): 65-68.
Liu FF, Li MX, Yan YC.Efficacy of neoadjuvant chemotherapy with continuous arterial infusion for intermediate and advanced oral cancer[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2022, 29(1): 65-68.
[22] 汪质良. 新辅助化疗结合局部放疗治疗中晚期食管癌的近期疗效及对血清肿瘤标志物水平的影响[J]. 临床合理用药, 2024, 17(22): 61-63, 73.
Wang ZL.The short-term efficacy of neoadjuvant chemotherapy combined with local radiotherapy in the treatment of advanced esophageal cancer and its impact on serum tumor marker levels[J]. Chinese Journal of Clinical Rational Drug Use, 2024, 17(22): 61-63, 73.